

Anti-EGFL7 Antibody (Parsatuzumab)

Introduction



Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody that binds to EGFL7 as an immunomodulator. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting angiogenesis and reducing vascular endothelial growth factor (VEGF) inhibition.

Product parameters

| Alternative Names | RG7414, MEGF0444A |
|---------------------|---|
| Target Accession | Q9UHF1 |
| Target | EGFL7 |
| CAS number | 1312797-14-0 |
| Molecular Weight | 148.22 kDa |
| Host | СНО |
| Reactivity | Human O |
| Conjugation | Unconjugated |
| Form | Liquid |
| Concentration | See label |
| Buffer System | 100 mM Pro 20 mM Arg pH 5.0. No preservative! |
| Clonality | Monoclonal |
| Purification | - |
| Isotype | IgG1 |
| Application | ELISA, FACS, Kinetics, Functional assay, Animal Model |
| Biological activity | - |
| Endotoxin | Less than 0.1 EU/ug determined by LAL method. |
| Sterilization | 0.2 μM filtered |
| Reconstitution | For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex. |
| Shipping | Dry ice |
| Storage | -80℃ |
| Expiration Date | 2 years |
| Note | Please avoid freeze-thaw cycles. |

Note

1. This product is for scientific research use only.









